Biogen Leans On Plegridy To Help Extend The Life Of Avonex
This article was originally published in The Pink Sheet Daily
Executive Summary
The drug maker reports positive late-stage data for its newest multiple sclerosis product. The pegylated interferon could help its existing injectable interferon franchise maintain share against new oral options.
You may also be interested in...
Biogen Turns To Plegridy As Avonex Sales Wane
The MS powerhouse got approval for its fourth treatment for the disease; the drug will help bolster the franchise while sales of some of the other drugs are eroded.
Biogen Bolsters Position In MS Now That Tecfidera Is A Blockbuster
The spec pharma’s latest MS offering surpasses $1 billion in sales as roll-out begins in Europe and focuses some of its resources toward its budding hemophilia franchise.
With Tecfidera, Biogen Idec Delivers Best MS Product Launch Yet
Biogen Idec blew past Wall Street estimates in its first quarter of revenue for its new, oral multiple sclerosis drug. But the biotech attributed much of the unexpected upside to quick conversions from another of its MS products, Tysabri.